Literature DB >> 3392422

Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia.

J E Kapusnik1, C J Hackbarth, H F Chambers, T Carpenter, M A Sande.   

Abstract

Single, large, daily aminoglycoside doses in animals are less toxic than conventional dosing, and higher drug concentrations in vitro produce more-rapid bacterial killing. Thus, we compared various aminoglycoside dosing schedules in neutropenic (n = 153) and nonneutropenic (n = 192) guinea pigs with Pseudomonas aeruginosa pneumonia. Equivalent tobramycin dosages were given: 5 mg/kg every 4 h or 30 mg/kg every 24 h. Animals were serially killed during therapy, and quantitative lung cultures were performed. Bacterial titers in lungs dropped rapidly in all tobramycin-treated animals, both neutropenic and nonneutropenic, during the initial 16 h of therapy. In nonneutropenic guinea pigs, lung titers remained constant despite continued 4-h dosing. With subsequent 24-h dosing, titers continued to drop, and by 72 h there were a significant number of animals with sterile lungs (P less than .01). In neutropenic guinea pigs given tobramycin every 24 h, bacterial regrowth occurred; thus, therapy was ineffective. Adding mezlocillin, however, suppressed regrowth; thus, combination therapy was superior (P less than .05).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3392422     DOI: 10.1093/infdis/158.1.7

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  53 in total

Review 1.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

2.  Once-daily aminoglycoside dosing: A new look at an old drug.

Authors:  J Conly; W Gold; S Shafran
Journal:  Can J Infect Dis       Date:  1994-09

3.  Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections.

Authors:  J S Solomkin; E P Dellinger; N V Christou; R W Busuttil
Journal:  Ann Surg       Date:  1990-11       Impact factor: 12.969

Review 4.  Once-daily aminoglycoside therapy.

Authors:  D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

5.  Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model.

Authors:  J G den Hollander; J W Mouton; M P van Goor; F P Vleggaar; H A Verbrugh
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

6.  Once-daily dosing of aminoglycosides.

Authors:  J Blaser; C König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-12       Impact factor: 3.267

7.  Duration and clinical relevance of postantibiotic effect in relation to the dosing interval.

Authors:  J G den Hollander; K Fuursted; H A Verbrugh; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

8.  Extended Interval Tobramycin Pharmacokinetics in a Pediatric Patient With Primary Ciliary Dyskinesia Presenting With an Acute Respiratory Exacerbation.

Authors:  Kristi L Higgins; Cady Noda; Jeremy S Stultz
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

Review 9.  Once-daily aminoglycoside administration: new strategies for an old drug.

Authors:  J M Kovarik; I M Hoepelman; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-09       Impact factor: 3.267

10.  Ceftriaxone-netilmicin combination in single-daily-dose treatment of experimental Escherichia coli endocarditis.

Authors:  B Fantin; B Pangon; G Potel; J M Vallois; F Caron; A Bure; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.